Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
source : Www.biospace.com save search
Cell MedX Corp. Announces New CEO and Directors and Debt Settlement
Published: 2023-12-19 (Crawled : 21:00) - biospace.com/
CMXC | $0.03 -63.33% 0
|
Manufacturing
|
| O: 0.0%
H: 415.38%
C: 330.77%
ceo cell
Avera Health and Theralink® Technologies Announce Strategic Collaboration to Accelerate Adoption of Precision Oncology and Personalized Cancer Care
Published: 2022-03-28 (Crawled : 17:00) - biospace.com/
THER | $0.001 62.5% 1.4M
|
n/a
|
| O: -80.0%
H: 400.0%
C: 300.0%
theralink health care collaboration cancer
Second Sight Medical Products, Inc. Receives FDA Approval for the Argus 2s Retinal Prosthesis System
Published: 2021-03-05 (Crawled : 15:00) - biospace.com/
EYES | $4.14 -0.24% 3.14%
|
Health Technology
|
| O: 60.14%
H: 331.88%
C: 152.84%
fda fda approval retina approval
Applied UV Announces Acquisition of the Airocide(R) Technology Platform for Airborne Pathogen Reduction
Published: 2021-02-09 (Crawled : 12:00) - biospace.com/
AUVI | $0.75 -2.84% -3.51% 93K
|
Health Technology
|
| O: 73.75%
H: 297.56%
C: 119.0%
acquisition platform
Ambrx Announces Encouraging Preliminary Safety and Efficacy Data Evaluating ARX788 in HER2 Positive Metastatic Breast Cancer Patients Who Progressed Following T-DM1 Treatment
Published: 2022-12-09 (Crawled : 14:00) - biospace.com/
AMAM 4 | $28.0 0.0% 1.4M
|
Professional, Scientific, and T...
|
| O: 185.44%
H: 288.03%
C: 288.03%
arx788 treatment breast positive cancer her2- her2 metastatic breast cancer
NeuroSense Therapeutics Receives FDA Clearance of IND for PrimeC for the Treatment of ALS
Published: 2022-03-21 (Crawled : 13:00) - biospace.com/
NRSN 4 d | $1.53 -4.38% -3.23% 73K
|
|
| O: 39.74%
H: 275.23%
C: 185.78%
treatment fda als clearance therapeutics fda clearance primec
Applied DNA Initiates Analytical Validation of PCR-based Diagnostic Test Specific to Monkeypox Virus
Published: 2022-08-02 (Crawled : 13:00) - biospace.com/
APDN | $0.3602 -4.91% -4.58% 120K
|
Commercial Services
|
| O: 95.3%
H: 227.07%
C: 110.53%
monkeypox test dna diagnostic virus
Q BioMed announces publication of pre-clinical research showing superior safety and efficacy against current first line therapy of its drug candidate Uttroside-B for liver cancer
Published: 2022-07-26 (Crawled : 13:20) - biospace.com/
QBIO | $0.0003 100.0% 30K
|
Professional, Scientific, and T...
|
| O: 0.25%
H: 200.0%
C: 200.0%
drug candidate research liver pre-clinical therapy cancer publication
Endo Announces First Patient Enrolled in Registry of Dupuytren's Contracture
Published: 2023-06-26 (Crawled : 12:00) - biospace.com/
ENDPQ 6 d | $0.0018 500.0% -50.0% 360K
|
n/a
|
| O: -50.0%
H: 200.0%
C: 100.0%
NeuroMetrix Receives FDA Breakthrough Device Designation for Treatment of Fibromyalgia with its Wearable Neurostimulation Technology
Published: 2021-07-20 (Crawled : 16:00) - biospace.com/
NURO | $3.52 -5.63% -4.34% 7.4K
|
Health Technology
|
| O: 23.62%
H: 197.77%
C: 149.13%
treatment fda device technology fibromyalgia designation
Phio Pharmaceuticals Presents Positive New Data on PH-894 Demonstrating Antitumor Efficacy in Model of PD-1 Refractory Disease at the AACR Annual Meeting 2022
Published: 2022-04-08 (Crawled : 19:00) - biospace.com/
PHIO | $0.6656 -1.23% -3.68% 49K
|
Health Technology
|
| O: -2.94%
H: 175.0%
C: 167.05%
ph-894 disease positive ph94
Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis
Published: 2023-10-17 (Crawled : 00:00) - biospace.com/
NKTX | $8.73 -0.11% -0.23% 900K
|
Health Technology
|
| O: -0.68%
H: 168.71%
C: 113.61%
partnership lupus natural cell therapeutics therapy
Annovis Bio Announces Positive Phase 2 Data - ANVS401 Improves Cognition in Alzheimer's Disease - Patients' Cognition Improved 3.3 Points on ADAS-Cog11
Published: 2021-05-21 (Crawled : 18:00) - biospace.com/
ANVS | $11.09 -4.64% 2.8% 160K
|
Health Technology
|
| O: 39.81%
H: 165.43%
C: 62.56%
disease alzheimer phase 2 positive alzheimer’s alzheimer's disease alzheimer's anvs401
Jasper Therapeutics Announces Positive Clinical Data from a Phase I/II Trial of Briquilimab as a Conditioning Treatment in Sickle Cell Disease and Beta Thalassemia
Published: 2023-01-03 (Crawled : 14:00) - biospace.com/
JSPR | $26.3 -5.12% -5.84% 110K
|
|
| O: 210.62%
H: 153.33%
C: 82.67%
treatment disease trial therapeutics positive
Endo Announces Approval of XCOPRI™ (cenobamate tablets) in Canada
Published: 2023-06-29 (Crawled : 12:20) - biospace.com/
ENDPQ 6 d | $0.0018 500.0% -50.0% 360K
|
n/a
|
| O: -50.0%
H: 150.0%
C: 125.0%
approval canada
Endo Announces Agreement with MAIA Pharmaceuticals to Distribute Bivalirudin Injection in Ready-to-Use Vials
Published: 2023-05-24 (Crawled : 13:00) - biospace.com/
ENDPQ 6 d | $0.0018 500.0% -50.0% 360K
|
n/a
|
| O: -60.0%
H: 150.0%
C: 150.0%
pharmaceuticals agreement injection
Virpax® Pharmaceuticals Receives FDA Response and Guidance on MMS019
Published: 2021-08-17 (Crawled : 14:15) - biospace.com/
VRPX | $3.5303 -0.56% 4.1% 1.5K
|
|
| O: 57.38%
H: 149.32%
C: 132.22%
fda fda response response
Updated Results from the Phase 1/2 Study of ESSA's Lead Candidate EPI-7386 in Combination with Enzalutamide Highlighted at the 29th Annual Prostate Cancer Foundation Scientific Retreat
Published: 2022-10-26 (Crawled : 14:00) - biospace.com/
EPIX | $7.3 -5.93% -3.05% 46K
|
Health Technology
|
| O: 19.19%
H: 148.78%
C: 135.12%
epi-7386 candidate results cancer study prostate cancer phase 1
ESSA Pharma Presents Preclinical Data for its First Generation Androgen Receptor N-Terminal Domain Degrader at the 34th EORTC-NCI-AACR Symposium
Published: 2022-10-26 (Crawled : 22:00) - biospace.com/
EPIX | $7.3 -5.93% -3.05% 46K
|
Health Technology
|
| O: 19.19%
H: 148.78%
C: 135.12%
pharma preclinical symposium
Endo Announces First Patient Enrolled in Registry of Peyronie's Disease
Published: 2023-07-20 (Crawled : 13:00) - biospace.com/
ENDPQ 6 d | $0.0018 500.0% -50.0% 360K
|
n/a
|
| O: 0.0%
H: 147.25%
C: 119.78%
disease
Gainers vs Losers
| 45% | 55% |
Top 10 Gainers
KAVL | $6.3 135.96% 57.45% 44M
|
Wholesale Trade
PXMD | $0.74 79.7% 44.16% 4.5M
|
Health Technology
DYNT | $0.3704 -5.27% 43.09% 5.5M
|
Health Technology
LGVN P 3 d | $2.93 73.37% 42.52% 56M
|
HUBC | $1.95 50.0% 32.99% 73M
|
n/a
SPCB | $0.4004 45.07% 31.75% 130M
|
Electronic Technology
ONVO | $1.35 33.65% 24.62% 53M
|
Health Technology
OMQS | $0.7038 35.35% 24.3% 3.5M
|
Professional, Scientific, and T...
SNPO | $10.54 29.48% 22.88% 3.9M
|
EEIQ | $1.16 27.46% 20.86% 6.9K
|
Educational Services
Your saved searches
Save your searches and get alerts when important news are released.